Research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-21 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Fully annexed localities (Auteuil, Batignolles-Monceau, Belleville, Bercy, Charonne, Grenelle, La Chapelle, La Villette, Montmartre, Passy, and Vaugirard): Everything disappeared along with the registers of the Parisian arrondissements—both originals and duplicates. Partially annexed localities (Aubervilliers, Bagnolet, Clichy, Gentilly, Ivry, Montrouge, Neuilly, Pantin, Le Pré-Saint-Gervais, Saint-Mandé, Saint-Ouen, and Vanves) or non-annexed areas (the rest of what is today known as the Petite Couronne): The originals, having been preserved locally, are still accessible in municipal archives unless transferred to the Departmental Archives of Hauts-de-Seine, Seine-Saint-Denis, or Val-de-Marne. The duplicates, however, were destroyed, except for the decennial tables covering 1793–1859.
MgCl2 → Mg(g) + Cl2(g) The temperatures at which this reaction is operated is between 680 and 750 °C. The magnesium chloride can be obtained using the Dow process, a process that mixes sea water and dolomite in a flocculator or by dehydration of magnesium chloride brines. The electrolytic cells are partially submerged in a molten salt electrolyte to which the produced magnesium chloride is added in concentrations between 6–18%. This process does have its share of disadvantages including production of harmful chlorine gas and the overall reaction being very energy intensive, creating environmental risks. The Pidgeon process is more advantageous regarding its simplicity, shorter construction period, low power consumption and overall good magnesium quality compared to the electrolysis method. In the United States, magnesium was once obtained principally with the Dow process in Corpus Christi TX, by electrolysis of fused magnesium chloride from brine and sea water. A saline solution containing Mg2+ ions is first treated with lime (calcium oxide) and the precipitated magnesium hydroxide is collected:
Stringing is perhaps the most crucial of these effects, and is often seen on adhesive tapes. Stringing occurs when a separation of two surfaces is beginning and molecules at the interface bridge out across the gap, rather than cracking like the interface itself. The most significant consequence of this effect is the restraint of the crack. By providing the otherwise brittle interfacial bonds with some flexibility, the molecules that are stringing across the gap can stop the crack from propagating. Another way to understand this phenomenon is by comparing it to the stress concentration at the point of failure mentioned earlier. Since the stress is now spread out over some area, the stress at any given point has less of a chance of overwhelming the total adhesive force between the surfaces. If failure does occur at an interface containing a viscoelastic adhesive agent, and a crack does propagate, it happens by a gradual process called "fingering", rather than a rapid, brittle fracture. Stringing can apply to both the diffusive bonding regime and the chemical bonding regime. The strings of molecules bridging across the gap would either be the molecules that had earlier diffused across the interface or the viscoelastic adhesive, provided that there was a significant volume of it at the interface.
Sources: en.wikipedia.org
=== Flows with large viscosity === For flows where viscous forces are dominant i.e. slow flows with large viscosity, a viscous pressure scale μU/L is used. In the absence of a free surface, the equation obtained is
=== Pharmacodynamics === KW-6356 is a selective A2A adenosine antagonist or inverse agonist displaying insurmountable antagonism of this adenosine subtype. Compared to the first generation A2A adenosine inverse agonist Istradefylline, KW-6356 possesses a 100-fold greater affinity for the A2A adenosine receptor and dissociates more slowly from the receptor. The metabolism of KW-6356 generates M6, an active metabolite with similar potency as a A2A antagonist/inverse agonist.
The LLNL chemistry, materials, and life science research focuses on chemical engineering, nuclear chemistry, materials science, and biology and bio-nanotechnology. Physics thrust areas include condensed matter and high-pressure physics, optical science and high energy density physics, medical physics and biophysics, and nuclear, particle and accelerator physics. In the area of energy and environmental science, Livermore's emphasis is on carbon and climate, energy, water and the environment, and the national nuclear waste repository. The LLNL engineering activities include micro- and nanotechnology, lasers and optics, biotechnology, precision engineering, nondestructive characterization, modeling and simulation, systems and decision science, and sensors, imaging and communications. LLNL is a computing organization with capabilities in computer science, software engineering, data science, modeling and simulation, information technology, and cyber security. Lawrence Livermore National Laboratory has worked out several energy technologies in the field of coal gasification, shale oil extraction, geothermal energy, advanced battery research, solar energy, and fusion energy. Main oil shale processing technologies worked out by the Lawrence Livermore National Laboratory are LLNL HRS (hot-recycled-solid), LLNL RISE (in situ extraction technology) and LLNL radiofrequency technologies.
Troika attempted to equalize the disciplines, keeping the effect intact and normalizing the cost, so a first-level power requires one blood point, a second-level two points, and so on. To balance the clans, the aristocratic Ventrue were only allowed to feed on noble blood, though this was changed to allow them to feed on lower-class humans, receiving less blood. During character creation, the game had an optional character biography with unique positive and negative characteristics (increasing one ability while limiting another). This was removed from the released game; Activision felt there was insufficient test time, and removing it was a more stable option. The team's previous experience was with turn-based combat games, and it struggled to develop a real-time combat system affected by customizable attributes and abilities that provided feedback to the player on how those statistics affected the battle. It initially found that by adhering too closely to the White Wolf source material rules for guns, where the effectiveness of a shot is determined in a contest between the player's skill and the opponent's defense, the firearms seemed broken; the player would not hit where they aimed. Troika found it difficult to mesh the available factors in a real-time setting. Melee combat had to deal with various melee weapons and animations and adjust for melee-on-melee and melee-on-ranged combat. Troika used first-person perspective to immerse the player in the setting, interacting face-to-face with the characters and seeing their facial reactions to the player.
Sources: en.wikipedia.org
=== 3-2-1 Backup Rule === The backup data needs to be stored, requiring a backup rotation scheme, which is a system of backing up data to computer media that limits the number of backups of different dates retained separately, by appropriate re-use of the data storage media by overwriting of backups no longer needed. The scheme determines how and when each piece of removable storage is used for a backup operation and how long it is retained once it has backup data stored on it. The 3-2-1 rule can aid in the backup process. It states that there should be at least 3 copies of the data, stored on 2 different types of storage media, and one copy should be kept offsite, in a remote location (this can include cloud storage). 2 or more different media should be used to eliminate data loss due to similar reasons (for example, optical discs may tolerate being underwater while LTO tapes may not, and SSDs cannot fail due to head crashes or damaged spindle motors since they do not have any moving parts, unlike hard drives). An offsite copy protects against fire, theft of physical media (such as tapes or discs) and natural disasters like floods and earthquakes. Physically protected hard drives are an alternative to an offsite copy, but they have limitations like only being able to resist fire for a limited period of time, so an offsite copy still remains as the ideal choice. Because there is no perfect storage, many backup experts recommend maintaining a second copy on a local physical device, even if the data is also backed up offsite.
=== Catalytic reforming === In catalytic reforming, a mixture of hydrocarbons with boiling points between 60 and 200 °C is blended with hydrogen gas and then exposed to a bifunctional platinum chloride or rhenium chloride catalyst at 500–525 °C and pressures ranging from 8–50 atm. Under these conditions, aliphatic hydrocarbons form rings and lose hydrogen to become aromatic hydrocarbons. The aromatic products of the reaction are then separated from the reaction mixture (or reformate) by extraction with any one of a number of solvents, including diethylene glycol or sulfolane, and benzene is then separated from the other aromatics by distillation. The extraction step of aromatics from the reformate is designed to produce aromatics with lowest non-aromatic components. Recovery of the aromatics, commonly referred to as BTX (benzene, toluene and xylene isomers), involves such extraction and distillation steps. In similar fashion to this catalytic reforming, UOP and BP commercialized a method from LPG (mainly propane and butane) to aromatics.
=== Anorexia nervosa === Anorexia nervosa (AN) is a common eating disorder characterized by low intake of food from fear of weight gain. Several complications are associated with this chronic disorder such as fatigue, insomnia, and low blood pressure. Intranasal administration of oxytocin in patients with AN significantly lowered food anticipation and eating concern.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.